Allergan (AGN) Tops Q1 EPS by 24c, Offers Q2 and Updated FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500, Nasdaq futures rise on tech boost
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- BOJ eyeing September rate hike, faster pace of tightening, sources say
Stifel Reiterates Hold Rating on Allergen (AGN), Remains Sidelined Awaiting Signs of a Strategic Shift
May 7, 2019 4:47 PM EDTStifel analyst Annabel Samimy reiterated a Hold rating and $175.00 price target on Allergen (NYSE: AGN).
The analyst comments "While AGN recognizes the need for change, there was no specific directive offered, yet. In the meantime, AGN remains focused on its core business,... More
